• Atara Biotherapeutics Inc ATRA.OQ ATRA.O is expected to show a fall in quarterly revenue when it reports results on May 7 (estimated) for the period ending March 31 2025

• The Thousand Oaks California-based company is expected to report a 79.3% decrease in revenue to $5.667 million from $27.36 million a year ago, according to the mean estimate from 3 analysts, based on LSEG data.

• ​LSEG's mean analyst estimate for Atara Biotherapeutics Inc is for a loss of $1.98 per share.

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

• The mean earnings estimate of analysts had fallen by about 3.7% in the last three months. ​

• Wall Street's median 12-month price target for Atara Biotherapeutics Inc is $17.00​, above​ its last closing price of $7.82. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

This summary was machine generated May 5 at 11:25 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)